South Korea's Boryung faces divestiture order over Sanofi Taxotere deal
MLex Summary: Boryung won conditional approval from the Korea Fair Trade Commission for its acquisition of worldwide commercial rights to Sanofi's Taxotere, an original docetaxel cancer drug used primarily to treat breast...To view the full article, register now.
Already a subscriber? Click here to view full article